

2005 (10)

Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave ME. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. *Journal of the National Cancer Institute*. 2005 Sep; 97 1287-1296

Duan W, Gabriel MY, Moussa M, Chan FL, Sakai H, Fong G, Xuan J. Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model. *Oncogene*. 2005 Feb; 24 1510-1524

Gabril MY, Duan W, Wu G, Moussa M, Izawa JI, Panchal CJ, Sakai H, Xuan JW. A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for preclinical studies. *Molecular Therapy*. 2005 Mar; 11 348-362

Ghavami S, Hashemi M, Kadkhoda K, Alavian SM, Bay GH, Los M. Apoptosis in liver diseases--detection and therapeutic applications. *Medical Science Monitor*. 2005 Nov; 11 (11) RA337-345

Hastie L, Wu G, Bygrave M, Yamasaki Y, Sakai H, Moussa M, Izawa J, Downey D, Greenberg N, Fenster A, Lacefield J, Xuan J. Three-dimensional ultrasound micro-imaging for preclinical studies using a transgenic prostate cancer mouse model. *Cancer Research*. 2005 May; 65 5268

Huizen IV, Wu G, Moussa M, Chin JL, Fenster A, Lacefield JC, Sakai H, Greenberg NM, Xuan JW. Establishment of a Serum Tumor Marker for Preclinical Trials of Mouse Prostate Cancer Models. *Clinical Cancer Research*. 2005 Nov; 11 7911-7919

Le Page C, Koumakpayi IH, Lessard L, Saad F, Mes-Masson AM. Independent role of phosphoinositol-3-kinase (PI3K) and casein kinase II (CK-2) in EGFR and Her-2-mediated constitutive NF-kappaB activation in prostate cancer cells. *Prostate*. 2005 Dec; 65 306-315

Maddika S, Booy EP, Johar D, Gibson SB, Ghavami S, Los M. Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway. *Journal of Cell Science*. 2005 Oct; 118 4485-4493

Mukhopadhyay UK, Senderowicz AM, Ferbeyre G. RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells. *Cancer Research*. 2005 Apr; 65 (7) 2872-2881

Tien Amy H, Xu Lixin, Helgason Cheryl D. Altered Immunity Accompanies Disease Progression in a Mouse Model of Prostate Dysplasia. *Cancer Research*. 2005 Apr; 65 (7) 2947-2955